EP2043999A2 - Procédé pour la préparation de chlorhydrate de venlafaxine - Google Patents

Procédé pour la préparation de chlorhydrate de venlafaxine

Info

Publication number
EP2043999A2
EP2043999A2 EP06847321A EP06847321A EP2043999A2 EP 2043999 A2 EP2043999 A2 EP 2043999A2 EP 06847321 A EP06847321 A EP 06847321A EP 06847321 A EP06847321 A EP 06847321A EP 2043999 A2 EP2043999 A2 EP 2043999A2
Authority
EP
European Patent Office
Prior art keywords
formula
methoxy phenyl
ethyl
vii
cyclohexanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06847321A
Other languages
German (de)
English (en)
Inventor
Parimal Hansmukh Desai
Narendra Jagannath Salvi
Bharat Kumar Surendra Patravale
Sudhir Tulshiram Patil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarti Healthcare Ltd
Original Assignee
Aarti Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarti Healthcare Ltd filed Critical Aarti Healthcare Ltd
Publication of EP2043999A2 publication Critical patent/EP2043999A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups

Definitions

  • the invention relates to a process for the preparation of venlafaxine hydrochloride.
  • the invention also relates to a process for the preparation of l-[2-amino-l-(4-methoxy phenyl)ethyl]cyclohexanol hydrochloride, a key intermediate of venlafaxine hydrochloride.
  • Venlafaxine is a non-tricyclic antidepressant chemically named as ( ⁇ )-l-[2-(dimethyl amino)- 1- (4-methoxy phenyl)ethyl] cyclohexanol. It is widely used to treat depression and antisocial disorders. It is a phenethylamine bicyclic derivative, chemically unrelated to tricyclic, tetracyclic or other available antidepressant agents. The antidepressant action of venlafaxine in humans is believed to be associated with its potentiation of neurotransmitter activity in the Central Nervous System.
  • hydrochloride salt of venlafaxine is convenient to be formulated into tablets, capsule, lozenges, powders or the like for oral administration and is currently available under the trade name Effexor as a racemic mixture of (+) and (-) enantiomers and is indicated for the treatment of depression.
  • Formula (VI) generally comprise the following steps :
  • Formula (IV) Symmetrical N-methylation of l-[2-amino-l-(4-methoxy phenyl) ethyl ] cyclohexanol of the formula (IV) in the presence of formic acid and formaldehyde (Eschweiler-Clarke reaction) to obtain Venlafaxin base of the formula (V);
  • venlafaxin base V
  • venlafaxin base V
  • Mallinckrodt Silica CC7 silica gel as a stationary phase
  • US '466 describes a process for the preparation of l-[cyano-l-(p-methoxy phenyl)methyl] cyclohexanol (III), a key intermediate of venlafaxine.
  • p-Methoxy phenyl acetonitrile is condensed with cyclohexanone in the presence of lithium di-isopropylamide at a temperature below 1O 0 C.
  • Lithium di-isopropylamide is also highly sensitive to moisture and air and unsafe besides being expensive.
  • CN1225356 describes a process for the preparation of l-[2-amino-l-(p-methoxyphenyl) ethyl] cyclohexanol, which is an important intermediate of venlafaxin.
  • the process uses sodium methylate, sodium ethylate, sodamide or sodium hydride as a substitute for n-butyl lithium or lithium diisopropylamide in the condensation step and borane as a substitute for catalyst Rhodium-aluminium trioxide in the hydrogenation step.
  • the reagents used in this process are also sensitive to moisture and air and unsafe.
  • US '912 describes a process for the preparation of venlafaxine which comprises reduction of the compound (III) with a formylating agent in the presence of protic solvent and Raney nickel catalyst at a temperature in the range of 30 to 60° C and at the hydrogen pressure in the range of 100 to 400 psi for 6 to 16 hours followed by purification of the venlafaxine base (V).
  • the yield of venlafaxine is reported to be in the range of 15 to 30 %. Further the un-reacted nitrile is required to be isolated from the reaction mixture.
  • US '502 describes a process for the preparation of venlafaxine hydrochloride from epoxy nitrile intermediates. This process comprises additional steps to prepare the epoxy nitrile derivatives.
  • WO0059851 describes a process for the preparation of venlafaxin and its hydrochloride salt by condensing p-methoxy phenyl acetonitrile with cyclohexanone in the presence of lithium diisopropyl amide to obtain the compound (III) followed by hydrogenation in the presence of cobalt chloride and sodium borohydride in methanol to obtain the compound (IV).
  • the compound (IV) is treated with formaldehyde and formic acid to give venlafaxine base (V), which is converted into its hydrochloride salt (VI).
  • the hydrogenation of the compound (III) in the presence of cobalt chloride and sodium borohydride is also disclosed in WO0032556.
  • the reagents used in this process are very expensive.
  • WO0250017 describes hydrogenation of the compound (III) in the presence of pretreated nickel or cobalt catalyst, alcohol and base such as NH 3 , NH 4 OH and NaOH.
  • the nickel or cobalt catalyst is pretreated with a carboxylic acid or a salt or an anhydride thereof or with an ammonium salt or a vanadium-, a tungsten-, or a molybdenum compound. Pretreatment procedure is cumbersome and time consuming. Further the hydrogenation reaction carried out under basic conditions at above room temperature results in the cracking of the starting nitrile compound to produce 4-methoxyphenyl acetontrile, which may undergo hydrogenation to produce 4-methoxy phenethyl amine as an impurity.
  • phenethyl amine or phenalkyl amine impurities are very similar to the end products of primary amines in terms of physical and chemical properties. Therefore, it is very difficult to separate the desired end products from the undesired ones.
  • WO 03050074 describes a process for the preparation of venlafaxine hydrochloride and its polymorphs.
  • P-methoxy phenyl acetonitrile is condensed with cylohexanone in the presence of inorganic base like alkaline earth metal hydroxides selected from lithium hydroxide, sodium hydroxide or potassium hydroxide to obtain l-[cyno-(4-methoxyphenyl)methyl]cyclohexanol followed by hydrogenation of the l-[cyno-(4-methoxyphenyl)methyl]cyclohexanol in the presence of Raney nickel catalyst at 60 psi under anhydrous ammonia in methanol at 30° C to obtain l-[2-amino-l-(4-methoxy phenyl)ethyl]cyclohexanol.
  • inorganic base like alkaline earth metal hydroxides selected from lithium hydroxide, sodium hydroxide or potassium hydroxide
  • the hydrogenated product is formylated with formic acid and formaldehyde to yield venlafaxine, which is converted into its hydrochloride salt.
  • Handling of the alkaline earth metal hydroxide like sodium hydroxide with a relatively strong base especially at industrial scale is very difficult.
  • US 20040181093 describes hydrogenation using a nickel or cobalt catalyst at temperature of about 5° C to 25° C to obtain compound (IV).
  • the yield of the compound (IV) is reported to be about 70 %.
  • US 2004/0106818 describes a process for the preparation of venlafaxin hydrochloride by carrying out the condensation in the presence of metal hydride followed by the reduction of the compound (III) by the metal hydrides or by the Raney nickel catalyst and hydrogen and isolation of venlafaxin base (IV).
  • the product obtained by hydrogenation of the compound (III) is purified by silica gel chromatography.
  • the base is converted into its hydrochloride salt (V).
  • US2005/0033088 describes a process for the preparation of venlafaxine hydrochloride in which reduction of the compound (III) is carried out in an organic acid selected from propionic acid, acetic acid or formic acid and Pd/C as a hydrogenation catalyst under a pressure of 5 to 25 kg/cm2 and at 50-55° C temperature.
  • the resulting acetate salt of the compound (IV) is formylated with formic acid and formaldehyde to give the final product (V).
  • the yield of the acetate salt of the compound (IV) is reported to be about 45-55%.
  • An object of the invention is to provide a simple, efficient and economical process for preparing venlafaxine hydrochloride in high yield with high purity.
  • Another object of the invention is to provide a process for preparing venlafaxine hydrochloride, which reduces formation of undesired impurities.
  • Another object of the invention is to provide a process for the preparation of venlafaxine hydrochloride, which eliminates elaborate work up and purification procedure like chromatography.
  • An object of the invention is to provide a simple, efficient and economical process for preparing l-[2-amino-l-(4-methoxy phenyl)ethyl]cyclohexanol hydrochloride in high yield with high purity.
  • Another object of the invention is to provide a process for preparing l-[2-amino-l-(4-methoxy phenyl)ethyl]cyclohexanol hydrochloride, which reduces formation of undesired impurities.
  • Formula (VI) the process comprising a. condensing p-methoxy phenyl acetonitrile of the formula (I) with cyclohexanone of the formula (II)
  • Formula (I) in the presence of a base selected from the group consisting of alkali metal alkoxides and a solvent selected from C 4 alcohol at - 10 to 5° C in the molar ratio of the base to p-methoxy phenyl acetonitrile or cyclohexanone in 0.1 to 0.4: 1, acidifying the reaction mixture with acetic acid to adjust the pH to 5 to 5.5 at - 5 to 5° C followed by addition of water and separation of the organic layer containing l-[cyano-l-(p- methoxy phenyl)methyl] cyclohexanol of the formula (III):
  • Formula (III) b. hydrogenating the organic layer with hydrogen in the presence of Raney nickel and ammonia at 10 to 12° C and pressure of 120-200 psi followed by distilling off the solvent to obtain a residue containing l-[2-amino-l-(4-methoxy phenyl)ethyl] cyclohexanol of the formula (IV):
  • Formula (VII) by dissolving the residue in an organic solvent at temperature of 0 to 5° C followed by adding hydrogen chloride solution in an organic solvent to adjust pH of the solution to 1 to 1.5 at the same temperature, adding anti-solvent to precipitate the compound (VII) while maintaining the same temperature and filtering out and drying the compound (VII); d.
  • Formula (VII) the process comprising a. condensing p-methoxy phenyl acetonitrile of the formula (I) with cyclohexanone of the formula (II):
  • Formula (III) b. hydrogenating the organic layer with hydrogen in the presence of Raney nickel and ammonia at 10 to 12° C and pressure of 120-200 psi followed by distilling off the solvent to obtain a residue containing l-[2-amino-l-(4-methoxy phenyl)ethyl] cyclohexanol of the formula (IV);
  • Formula (VII) by dissolving the residue in an organic solvent at temperature of 0 to 5° C followed by adding alcoholic solution of hydrogen chloride to adjust pH of the solution to 1 to 1.5 at the same temperature, adding anti-solvent to precipitate the compound (VII) while maintaining the same temperature and filtering out and drying the compound (VII).
  • the alkali metal oxide used in step (a) is selected from sodium n-butoxide, potassium n-butoxide, sodium t-butoxide, potassium t-butoxide.
  • the alkali metal alkoxide used in the condensation step (a) is sodium butoxide and is used in the molar ratio of 0.1 : 1 with respect to p-methoxy phenyl acetonitrile or cyclohexanone.
  • the C 4 alcohol used in step (a) is selected from n-butanol, isobutanol or tert-butanol.
  • the condensation step (a) is selected from n-butanol, isobutanol or tert-butanol.
  • step (a) is carried out at a temperature in the range of- 10 to -5° C.
  • the hydrogenation step (b) is carried out at the pressure of 120psi.
  • the catalyst is filtered and solvent is removed by distillation under vacuum to obtain residue.
  • the organic solvent used to dissolve the residue in step (c) is ethyl acetate, di-isopropyl ether or n-butanol.
  • the hydrogen chloride solution in an organic solvent used to adjust the pH of the solution in step (c) is hydrogen chloride solution in isopropyl alcohol, di-isopropyl ether or n- butanol.
  • the anti-solvent used to precipitate the compound (IV) in step (c) is n- pentane, n-hexane or n-heptane, acetone or ethyl methyl ketone.
  • the condensation step (a) is carried out with reduced amount of the base (0.1 to 0.4 mole of the base with respect to 1 mole of p-methoxy phenyl acetonitrile or cyclohexanone).
  • 0.1 to 0.4 mole of the base is found to be sufficient to activate 1 mole of p- methoxy phenyl acetonitrile.
  • the amount of the base is reduced, self condensation of two molecules cyclohexanone and p-methoxy phenyl acetonitrile is eliminated and formation of undesired side products is reduced.
  • the venlafaxine hydrochloride is obtained in high yield of 94 to 95 % with high purity of 99.2 to 99.9 %.
  • the l-[2-amino-l-(4-methoxy phenyl)ethyl]cyclohexanol hydrochloride (VII) is also obtained in high yield of 88 to 90 % and purity of 94 to 95 %
  • the process of the invention does not isolate the intermediate (III) and thus reduces the number of process step and process duration.
  • the venlafaxine hydrochloride obtained is a white crystalline solid and does not require any purification.
  • the process is also simple, easy and convenient to carry out, efficient and economical.
  • the reaction mixture was acidified (pH about 5.5) with glacial acetic acid while maintaining the temperature in the range of -5 to 5 0 C. 30 ml of water was added to the reaction mixture and was stirred for 10 minutes. The biphasic reaction mixture was allowed to settle and the organic layer was separated. To this organic layer, 12 gm Raney nickel catalyst and 10 % ammonical butanol (100 ml) were added. The reaction mixture was transferred to autoclave vessel. H 2 gas was flushed to increase the pressure to 120psi. The mixture was slowly heated at temperature of 10 to 12 0 C under the hydrogen pressure of 120 psi for 6 to 7 hrs. The completion of the reaction was monitored with thin layer chromatography.
  • reaction mixture 9 to 9.5 and stirred it for 30 minutes at 0 to 5 0 C.
  • the reaction mixture was filtered and solvent was distilled out.
  • 1 ml of water, 20 gm of Formic acid, and 14 gm of Formaldehyde were added while maintaining the temperature at 20-25 0 C.
  • the reaction mixture was refluxed for about 14 to 15 hrs at a temperature of about 95 to 100 0 C.
  • the reaction was monitored with thin layer chromatography.
  • the pH of reaction mixture was adjusted to 9-9.5 by using 20% sodium hydroxide followed by addition of 20 ml of Ethyl acetate to the reaction mixture.
  • the reaction mixture was heated to 4O 0 C for 30 minutes while stirring and the organic layer was separated out.
  • the solvent was distilled out from the organic layer to obtain residue.
  • the residue was dissolved in 20 ml of ethyl acetate.
  • the pH of reaction mixture was adjusted to 1-1.5 by adding 20 % hydrogen chloride in isopropanol to precipitate venlfaxine hydrochloride.
  • the precipitated product was filtered and dried at 50-55 0 C
  • the biphasic reaction mixture was allowed to settle and the organic layer was separated.
  • 12 gm Raney nickel catalyst and 10 % ammonical isobutanol (100 ml) were added.
  • the reaction mixture was transferred to autoclave vessel.
  • H 2 gas was flushed to increase the pressure to 120psi.
  • the mixture was slowly heated at temperature of 10 to 12 0 C under the hydrogen pressure of 120 psi for 6 to 7 hrs.
  • the completion of the reaction was monitored with thin layer chromatography.
  • the catalyst was filtered off and the solvent was distilled off to obtain residue. The residue was dissolved in 60 ml ethyl acetate and cooled to 0-5 0 C.
  • reaction mixture 9 to 9.5 and stirred it for 30 minutes at 0 to 5 0 C.
  • the reaction mixture was filtered and solvent was distilled out.
  • 1 ml of water, 20 gm of Formic acid, and 14 gm of Formaldehyde were added while maintaining the temperature at 20-25 0 C.
  • the reaction mixture was refluxed for about 14 to 15 hrs at a temperature of about 95- 100 0 C.
  • the reaction was monitored with thin layer chromatography.
  • the pH of reaction mixture was adjusted to 9-9.5 by using 20% sodium hydroxide followed by addition of 20 ml of Ethyl acetate to the reaction mixture.
  • the reaction mixture was heated to 4O 0 C for 30 minutes while stirring and the organic layer was separated out.
  • the solvent was distilled out from the organic layer to obtain residue.
  • the residue was dissolved in 20 ml of ethyl acetate.
  • the pH of reaction mixture was adjusted to 1-1.5 by adding 20 % hydrogen chloride in isopropanol to precipitate venlfaxine hydrochloride.
  • the precipitated product was filtered and dried at 50-55 0 C
  • the biphasic reaction mixture was allowed to settle and the organic layer was separated.
  • 12 gm Raney nickel catalyst and 10 % ammonical tert-butanol (100 ml) were added.
  • the reaction mixture was transferred to autoclave vessel.
  • H 2 gas was flushed to increase the pressure to 120psi.
  • the mixture was slowly heated at temperature of 10 to 12 0 C under the hydrogen pressure of 120 psi for 6 to 7 hrs.
  • the completion of the reaction was monitored with thin layer chromatography.
  • the catalyst was filtered off and the solvent was distilled off to obtain residue. The residue was dissolved in 60 ml ethyl acetate and cooled to 0-5 0 C.
  • reaction mixture was adjusted to 9-9.5 by using 20% sodium hydroxide followed by addition of 20 ml of Ethyl acetate to the reaction mixture.
  • the reaction mixture was heated to 4O 0 C for 30 minutes while stirring and the organic layer was separated out.
  • the solvent was distilled out from the organic layer to obtain residue.
  • the residue was dissolved in 20 ml of ethyl acetate.
  • the pH of reaction mixture was adjusted to 1-1.5 by adding 20 % hydrogen chloride in isopropanol to precipitate venlfaxine hydrochloride.
  • the precipitated product was filtered and dried at 50-55 0 C % Yield : 94.1 %

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé servant à préparer du chlorhydrate de venlafaxine et également un procédé servant à préparer du chlorhydrate de l-[2-amino-l-(4-méthoxyphényl)éthyl]cyclohexanol, un intermédiaire du chlorhydrate de venlafaxine. On condense du p-méthoxyphénylacétonitrile avec de la cyclohexanone en présence d'une base sélectionnée parmi des alcoolates métalliques alcalins et d'un solvant sélectionné parmi des alcools en C4 à une température de -10 à -5°C pour obtenir du l-[cyano-l-(p-méthoxyphényl)éthyl]cyclohexanol, qui est directement converti en l-[2-amino-l-(4-méthoxyphényl)éthyl]cyclohexanol sans être isolé. La proportion molaire de la base par rapport au p-méthoxyphénylacétonitrile ou à la cyclohexanone utilisés est de 0,1 à 0,4:1. Le l-[2-amino-l-(4-méthoxyphényl)éthyl]cyclohexanol est converti en son sel de chlorhydrate puis formylé en venlafaxine sous forme de base. La venlafaxine sous forme de base est encore convertie en son sel à savoir le chlorhydrate de venlafaxine. A la fois le chlorhydrate de venlafaxine et le chlorhydrate de l-[2-amino-l-(4-méthoxyphényl)éthyl]cyclohexanol sont obtenus avec un rendement de production élevé et avec une pureté élevée.
EP06847321A 2005-11-30 2006-11-27 Procédé pour la préparation de chlorhydrate de venlafaxine Withdrawn EP2043999A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1483MU2005 2005-11-30
PCT/IN2006/000474 WO2007069277A2 (fr) 2005-11-30 2006-11-27 Procédé pour la préparation de chlorhydrate de venlafaxine

Publications (1)

Publication Number Publication Date
EP2043999A2 true EP2043999A2 (fr) 2009-04-08

Family

ID=38008031

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06847321A Withdrawn EP2043999A2 (fr) 2005-11-30 2006-11-27 Procédé pour la préparation de chlorhydrate de venlafaxine

Country Status (2)

Country Link
EP (1) EP2043999A2 (fr)
WO (1) WO2007069277A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103382159A (zh) * 2013-08-16 2013-11-06 成都倍特药业有限公司 盐酸文拉法辛的制备方法
CN107652191B (zh) * 2017-11-24 2020-05-19 常州沃腾化工科技有限公司 一种文拉法辛中间体的纯化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
CN1225356A (zh) * 1998-12-15 1999-08-11 华东理工大学 1－[2－氨基－1－(对甲氧苯基)乙基]环己醇的合成方法
CN1232501C (zh) * 2002-11-29 2005-12-21 重庆凯林制药有限公司 用于制备万拉法新中间体的环己醇衍生物的制备工艺
TWI306092B (en) * 2003-03-11 2009-02-11 Wyeth Corp Process for preparation of phenethylamine derivatives
PE20050954A1 (es) * 2003-10-02 2005-12-20 Wyeth Corp Proceso para la preparacion de compuestos de 1-[ciano(fenil)metil]-ciclohexanol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007069277A3 *

Also Published As

Publication number Publication date
WO2007069277A2 (fr) 2007-06-21
WO2007069277A3 (fr) 2007-07-26

Similar Documents

Publication Publication Date Title
US7563931B2 (en) Process for preparation of phenethylamine derivatives
CN107805205B (zh) 一种(r)-3-氨基丁醇的制备方法
AU2003277353B2 (en) Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
WO2001030742A1 (fr) Synthese amelioree de sertraline racemique
US6350912B1 (en) One pot process for the preparation of 1-[2-dimethylamino-(4-methoxyphenyl)-ethyl]cyclohexanol
US20070129562A1 (en) Process for the preparation of highly pure 1-[2- dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride
WO2007069277A2 (fr) Procédé pour la préparation de chlorhydrate de venlafaxine
US20050033088A1 (en) Process for the preparation of phenethylamine derivative, an intermediate of Venlafaxine hydrochloride
US20050148792A1 (en) Process for the preparation of gabapentin
WO2010046808A2 (fr) Procédé de préparation de chlorhydrate de venlafaxine
US7470816B2 (en) Tramadol recovery process
US6846957B2 (en) Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor
WO2006067808A1 (fr) Procede ameliore pour la production d’un intermediaire d’un agent antidepresseur
US6765114B1 (en) Process for the synthesis of 1-(aminomethyl)cyclohexyl-acetic acid
WO2008043269A1 (fr) Procédé de préparation de 1-(3-méthyloxybenzène)éthylamine à activité optique
US4045560A (en) 2-Morpholine containing methano or ethano anthracene compounds
WO2005121074A2 (fr) Procedes pour la preparation de chlorhydrate de sertraline
US20100094055A1 (en) Process for the preparation of phenethylamine derivatives
EP1238965B1 (fr) Procédé de préparation du 1-(2-diméthylamino-(4-méthoxyphényl)-éthyl)cyclohexanol
WO2007049302A2 (fr) Procede ameliore pour la preparation de venlafaxine pure
EP1503978A1 (fr) Procede de fabrication de sertraline
CN116354835A (zh) 一种盐酸文拉法辛ep杂质h的制备方法
EP1140793A1 (fr) Procede de synthese d'acide acetique 1-(aminomethyl)-cyclohexene
NZ578186A (en) Improved process for the preparation of phenethylamine derivatives in particular venlafaxine hydrochloride or its metabolite odv
EP1401799A1 (fr) Procede de production de methylamine aromatique halogenee

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081020

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20100707

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101118